CDK inhibitors may improve immune therapy effectiveness for recurrent breast cancer
Spain: Expert warns that virus surge could follow parties
10 May 2021PARP inhibitor shrinks tumors in pancreatic cancer patients with mutations
10 May 2021CDK inhibitors may improve immune therapy effectiveness for recurrent breast cancer
A class of drugs that inhibits breast cancer progression when used with hormonal therapy might also boost the effectiveness of immune therapy in cases of recurrent, metastatic breast cancer, according to a new study led by researchers at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC—James).
